Evidence map›Paper›PMID 38273965›Full record

ArticleAdvances in redox research2022

Extracellular superoxide dismutase (EC-SOD) R213G variant reduces mitochondrial ROS and preserves mitochondrial function in bleomycin-induced lung injury: EC-SOD R213G variant and intracellular redox regulation.

Hanan Elajaili, Laura Hernandez-Lagunas, Peter Harris, Genevieve C Sparagna, Raleigh Jonscher, Denis Ohlstrom, Carmen C Sucharov, Russell P Bowler, Hagir Suliman, Kristofer S Fritz and 2 more

Open access · goldAbstract read
In one paragraph

Article in Advances in redox research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Hanan ElajailiCardiovascular Pulmonary Research Laboratories and Pediatric Critical Care Medicine, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Laura Hernandez-LagunasCardiovascular Pulmonary Research Laboratories and Pediatric Critical Care Medicine, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Peter HarrisDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Genevieve C SparagnaDivision of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Raleigh JonscherDivision of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Denis OhlstromCardiovascular Pulmonary Research Laboratories and Pediatric Critical Care Medicine, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Carmen C SucharovDivision of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Russell P BowlerDepartment of Medicine, National Jewish Health, Denver, Colorado.
Hagir SulimanDepartments of Anesthesiology and Pathology, Duke University School of Medicine, Durham, North Carolina.
Kristofer S FritzDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
James R RoedeDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Eva S NozikCardiovascular Pulmonary Research Laboratories and Pediatric Critical Care Medicine, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
University of Colorado Anschutz Medical Campus · USDuke University · USNational Jewish Health · US

Funding

Impact of Insufficient Vascular EC-SOD in Pulmonary HypertensionR01HL086680 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI NOZIK, EVA S. · 2008 to 2017
$4.7M
SOD3 regulation of redox sensitive signaling in pulmonary vascular diseasesR35HL139726 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI NOZIK, EVA S. · 2018 to 2024
$4.1M
Investigating the role of the R213G SOD3 polymorphism in lung diseaseR01HL111288 · NHLBI · NATIONAL JEWISH HEALTH · PI BOWLER, RUSSELL PAUL · 2012 to 2015
$1.1M
NHLBI NIH HHS R01 HL086680NHLBI NIH HHS R01 HL111288NHLBI NIH HHS R35 HL139726
6 · The paper itself

Abstract

Extracellular superoxide dismutase (EC-SOD) is highly expressed in the lung and vasculature. A common human single nucleotide polymorphism (SNP) in the matrix binding region of EC-SOD leads to a single amino acid substitution, R213G, and alters EC-SOD tissue binding affinity. The change in tissue binding affinity redistributes EC-SOD from tissue to extracellular fluids. Mice (R213G mice) expressing a knock-in of this EC-SOD SNP exhibit elevated plasma and reduced lung EC-SOD content and activity and are protected against bleomycin-induced lung injury and inflammation. It is unknown how the redistribution of EC-SOD alters site-specific redox-regulated molecules relevant for protection. In this study, we tested the hypothesis that the change in the local EC-SOD content would influence not only the extracellular redox microenvironment where EC-SOD is localized but also protect the intracellular redox status of the lung. Mice were treated with bleomycin and harvested 7 days post-treatment. Superoxide levels, measured by electron paramagnetic resonance (EPR), were lower in plasma and Bronchoalveolar lavage fluid (BALF) cells in R213G mice compared to wild-type (WT) mice, while lung cellular superoxide levels in R213G mice were not elevated post-bleomycin compared to WT mice despite low lung EC-SOD levels. Lung glutathione redox potential (E

Indexed as

cardiolipinEC-SODmitochondriaR213Gredox potential

Identifiers

PMID38273965
PMCPMC10810244
OpenAlexW4220676864

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.